Urteste (URT) Stock Overview

Engages in the research and development of diagnostic tests for cancers. More details

URT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

URT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Urteste S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Urteste
Historical stock prices
Current Share Pricezł49.20
52 Week Highzł107.00
52 Week Lowzł45.00
Beta-0.056
1 Month Change-3.53%
3 Month Change-38.04%
1 Year Change-43.32%
3 Year Change-44.09%
5 Year Changen/a
Change since IPO-50.20%

Recent News & Updates

Here's Why We're Watching Urteste's (WSE:URT) Cash Burn Situation

May 27
Here's Why We're Watching Urteste's (WSE:URT) Cash Burn Situation

Is Urteste (WSE:URT) In A Good Position To Invest In Growth?

Dec 07
Is Urteste (WSE:URT) In A Good Position To Invest In Growth?

Urteste (WSE:URT) Is In A Good Position To Deliver On Growth Plans

Jul 19
Urteste (WSE:URT) Is In A Good Position To Deliver On Growth Plans

Recent updates

Here's Why We're Watching Urteste's (WSE:URT) Cash Burn Situation

May 27
Here's Why We're Watching Urteste's (WSE:URT) Cash Burn Situation

Is Urteste (WSE:URT) In A Good Position To Invest In Growth?

Dec 07
Is Urteste (WSE:URT) In A Good Position To Invest In Growth?

Urteste (WSE:URT) Is In A Good Position To Deliver On Growth Plans

Jul 19
Urteste (WSE:URT) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

URTPL BiotechsPL Market
7D7.0%0.9%-1.3%
1Y-43.3%-13.1%13.3%

Return vs Industry: URT underperformed the Polish Biotechs industry which returned -13.1% over the past year.

Return vs Market: URT underperformed the Polish Market which returned 13.3% over the past year.

Price Volatility

Is URT's price volatile compared to industry and market?
URT volatility
URT Average Weekly Movement9.5%
Biotechs Industry Average Movement5.8%
Market Average Movement5.3%
10% most volatile stocks in PL Market11.7%
10% least volatile stocks in PL Market3.3%

Stable Share Price: URT's share price has been volatile over the past 3 months compared to the Polish market.

Volatility Over Time: URT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

FoundedEmployeesCEOWebsite
202133Grzegorz Stefanskiwww.urteste.com

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, stomach, lung, oesophagus, ovary, endometrium, blood, breast, and nervous system cancer. The company was incorporated in 2021 and is based in Gdansk, Poland.

Urteste S.A. Fundamentals Summary

How do Urteste's earnings and revenue compare to its market cap?
URT fundamental statistics
Market capzł69.50m
Earnings (TTM)-zł3.04m
Revenue (TTM)zł1.54m
45.1x
P/S Ratio
-22.8x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
URT income statement (TTM)
Revenuezł1.54m
Cost of Revenuezł252.00k
Gross Profitzł1.29m
Other Expenseszł4.33m
Earnings-zł3.04m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.16
Gross Margin83.60%
Net Profit Margin-197.85%
Debt/Equity Ratio0%

How did URT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/11 18:10
End of Day Share Price 2025/07/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Urteste S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sylwia JaskiewiczDom Maklerski Banku Ochrony Srodowiska S.A.